These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30342319)

  • 21. Strategies for the isolation and characterization of antibacterial lantibiotics.
    Jabes D; Donadio S
    Methods Mol Biol; 2010; 618():31-45. PubMed ID: 20094856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The dawning of a 'Golden era' in lantibiotic bioengineering.
    Field D; Hill C; Cotter PD; Ross RP
    Mol Microbiol; 2010 Dec; 78(5):1077-87. PubMed ID: 21091497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Covalent structure of mutacin 1140 and a novel method for the rapid identification of lantibiotics.
    Smith L; Novák J; Rocca J; McClung S; Hillman JD; Edison AS
    Eur J Biochem; 2000 Dec; 267(23):6810-6. PubMed ID: 11082191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of new class III lantibiotics--erythreapeptin, avermipeptin and griseopeptin from Saccharopolyspora erythraea, Streptomyces avermitilis and Streptomyces griseus demonstrates stepwise N-terminal leader processing.
    Völler GH; Krawczyk JM; Pesic A; Krawczyk B; Nachtigall J; Süssmuth RD
    Chembiochem; 2012 May; 13(8):1174-83. PubMed ID: 22556031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in the arsenal of tools available enabling the discovery of novel lantibiotics with therapeutic potential.
    Sandiford SK
    Expert Opin Drug Discov; 2014 Mar; 9(3):283-97. PubMed ID: 24410252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carboxyl Analogue of Mutacin 1140, a Scaffold for Lead Antibacterial Discovery.
    Escano J; Ravichandran A; Salamat B; Smith L
    Appl Environ Microbiol; 2017 Jul; 83(14):. PubMed ID: 28500042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complete alanine scanning of the two-component lantibiotic lacticin 3147: generating a blueprint for rational drug design.
    Cotter PD; Deegan LH; Lawton EM; Draper LA; O'Connor PM; Hill C; Ross RP
    Mol Microbiol; 2006 Nov; 62(3):735-47. PubMed ID: 17076667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery, Production and Modification of Five Novel Lantibiotics Using the Promiscuous Nisin Modification Machinery.
    van Heel AJ; Kloosterman TG; Montalban-Lopez M; Deng J; Plat A; Baudu B; Hendriks D; Moll GN; Kuipers OP
    ACS Synth Biol; 2016 Oct; 5(10):1146-1154. PubMed ID: 27294279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Substrate Specificity of a Methyltransferase Involved in the Biosynthesis of the Lantibiotic Cacaoidin.
    Liang H; Luo Y; van der Donk WA
    Biochemistry; 2024 Oct; 63(19):2493-2505. PubMed ID: 39271288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increasing the success rate of lantibiotic drug discovery by Synthetic Biology.
    Montalbán-López M; Zhou L; Buivydas A; van Heel AJ; Kuipers OP
    Expert Opin Drug Discov; 2012 Aug; 7(8):695-709. PubMed ID: 22680308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Posttranslationally modified bacteriocins--the lantibiotics.
    Guder A; Wiedemann I; Sahl HG
    Biopolymers; 2000; 55(1):62-73. PubMed ID: 10931442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural characterization of the highly cyclized lantibiotic paenicidin A via a partial desulfurization/reduction strategy.
    Lohans CT; Huang Z; van Belkum MJ; Giroud M; Sit CS; Steels EM; Zheng J; Whittal RM; McMullen LM; Vederas JC
    J Am Chem Soc; 2012 Dec; 134(48):19540-3. PubMed ID: 23167271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The biology of lantibiotics from the lacticin 481 group is coming of age.
    Dufour A; Hindré T; Haras D; Le Pennec JP
    FEMS Microbiol Rev; 2007 Mar; 31(2):134-67. PubMed ID: 17096664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BaPreS: a software tool for predicting bacteriocins using an optimal set of features.
    Akhter S; Miller JH
    BMC Bioinformatics; 2023 Aug; 24(1):313. PubMed ID: 37592230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel lantibiotics and their pre-peptides.
    Nes IF; Tagg JR
    Antonie Van Leeuwenhoek; 1996 Feb; 69(2):89-97. PubMed ID: 8775969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure and dynamics of the lantibiotic mutacin 1140.
    Smith L; Zachariah C; Thirumoorthy R; Rocca J; Novák J; Hillman JD; Edison AS
    Biochemistry; 2003 Sep; 42(35):10372-84. PubMed ID: 12950164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deuterium labeled peptides give insights into the directionality of class III lantibiotic synthetase LabKC.
    Krawczyk B; Ensle P; Müller WM; Süssmuth RD
    J Am Chem Soc; 2012 Jun; 134(24):9922-5. PubMed ID: 22687055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lantibiotic production by pathogenic microorganisms.
    Daly KM; Cotter PD; Hill C; Ross RP
    Curr Protein Pept Sci; 2012 Sep; 13(6):509-23. PubMed ID: 22708496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lantibiotics and microcins: polypeptides with unusual chemical diversity.
    Jack RW; Jung G
    Curr Opin Chem Biol; 2000 Jun; 4(3):310-7. PubMed ID: 10826980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A system for the random mutagenesis of the two-peptide lantibiotic lacticin 3147: analysis of mutants producing reduced antibacterial activities.
    Field D; Collins B; Cotter PD; Hill C; Ross RP
    J Mol Microbiol Biotechnol; 2007; 13(4):226-34. PubMed ID: 17827973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.